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Functional Inactivation of CYLD Promotes the
Metastatic Potential of Tumor Epidermal Cells
Josefa P. Alameda1, M. Jesu´s Ferna´ndez-Acen˜ero2, Rita M. Quintana1, Angustias Page1, A´ngel Ramı´rez1,
Manuel Navarro1 and M. Llanos Casanova1
CYLD is a tumor-suppressor gene mutated in the skin appendage tumors cylindromas, trichoepitheliomas, and
spiradenomas. We have performed in vivo metastasis assays in nude mice and found that the loss of the
deubiquitinase function of CYLD in squamous cell carcinoma (SCC) cells greatly enhances the lung metastatic
capability of these cells. These metastases showed several characteristics that make them distinguishable from
those carrying a functional CYLD, such as robust angiogenesis, increased expression of tumor malignancy
markers of SCCs, and a decrease in the expression of the suppressor of metastasis Maspin. Restoration of Maspin
expression in the epidermal SCC cells defective in CYLD deubiquitination function significantly reduces their
ability to form metastases, thereby suggesting that the decrease in the levels of Maspin expression plays an
important role in the acquisition of metastatic potential of these cells. In addition, we have characterized Maspin
downregulation in cylindromas, trichoepitheliomas, and spiradenomas carrying functional inactivating mutations
of CYLD, also providing an evidence of the correlation between impaired CYLD function and Maspin decreased
expression in vivo in human tumors.
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INTRODUCTION
CYLD is a tumor-suppressor gene mutated in hereditary
syndromes that predisposes patients for the development of
skin appendage tumors such as cylindromas, trichoepithelio-
mas, and spiradenomas (Gerretsen et al., 1995; Bignell et al.,
2000; Lee et al., 2005; Young et al., 2006). Here we refer to
all of these tumoral manifestations with the generic name of
cylindromatosis. In addition to inherited tumors, these types of
neoplasias are also found as sporadic tumors. CYLD functions
as a deubiquitinase that removes the lysine-63 polyubiquitin
chains from an array of target proteins involved in signal
transduction and gene regulation (Brummelkamp et al., 2003;
Kovalenko et al., 2003; Trompouki et al., 2003). Most of the
mutations within the CYLD locus are found in the catalytic
residues of ubiquitin hydrolase (Massoumi and Paus, 2007;
Saggar et al., 2008).
We have recently reported on the role of CYLD in the
homeostasis of the skin: it develops an important function in
the maintenance of epidermal polarity, keratinocyte differen-
tiation, and apoptosis (Alameda et al., 2011a).
Nonmelanoma skin cancer (NMSC), i.e., basal cell carci-
nomas and cutaneous squamous cell carcinomas (SCCs), is the
most common form of cancer in the Caucasian population
(Christenson et al., 2005). SCCs account for B20% of all
cutaneous malignancies, and may be very aggressive and
invasive (Moller et al., 1979). Among the factors considered to
play a role as SCC promoters, we have recently shown that the
diminished function of CYLD in tumor epidermal cells
worsens the prognosis of malignant skin tumors through
enhancement of the expression of angiogenic factors and
increase in the nuclear localization of Bcl3, p52, and
b-catenin (Alameda et al., 2010, 2011a). In addition, we
have shown that wild-type CYLD overexpression in human
SCC cells reverts the malignant phenotype of the tumors
(Alameda et al., 2011a). It has also been reported that mice
lacking Cyld are highly susceptible to development of
chemically induced benign skin tumors (Massoumi et al.,
2006), and transgenic mice expressing a catalytically inactive
mutant CYLD develop tumors of increased malignancy
relative to nontransgenic mice (De Marval et al., 2011).
Here we have analyzed whether CYLD may also function as
an inhibitor of metastasis of SCCs. To this aim, we have
performed in vivo metastasis assays in nude mice and found
that the expression in SCC cells of a mutant CYLD lacking the
deubiquitinase function (and acting as a dominant negative
interfering with the endogenous CYLD function) greatly
enhances the lung metastatic capability of these cells. These
metastases showed a strong angiogenesis and the induction of
markers of high aggressiveness of SCCs such as Snail and
keratins K8 and K13. In addition, they also exhibit a
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downregulation of the inhibitor of metastasis Maspin, and we
provide evidences suggesting that this decreased expression of
Maspin is, at least in part, responsible for the enhancement of
the metastatic capacity of the SCC cells lacking the
deubiquitinase function of CYLD.
Maspin is a protein of the Serpin family that acts as a tumor
suppressor inhibiting cellular motility, invasiveness, and
angiogenesis, and providing sensitivity to apoptosis in tumor
cells (Bailey et al., 2006; Khalkhali-Ellis, 2006). Maspin
expression predicts a better prognosis in different types of
cancers: breast, prostate, colon, oral squamous cell
carcinoma, lung, larynx, malignant melanoma, and ovarian
cancer (Shi et al., 2001; Futscher et al., 2004). Maspin also
acts as suppressor of metastasis in different types of cancer
such as prostate, liver, and breast (Luo et al., 2007; Stark et al.,
2010). Little is known about the expression of Maspin in skin
and skin cancer. We have recently found that the diminished
expression of Maspin in mouse skin tumors is a potential cause
for NMSC progression (Alameda et al., 2011b).
Our present data show an inverse relationship between the
grade of malignancy of tumor epidermal cells and the level of
expression of Maspin. We have also found a correlation
between forced CYLD functional inactivation in epidermal
SCC cells and a decreased Maspin expression. This correlation
is also found in vivo in cylindromatosis tumors carrying a
mutated CYLD gene. In addition, we have found a physical
interaction between CYLD and Maspin.
RESULTS
The inhibition of CYLD function in tumor epidermal cells
enhances its capacity to generate lung metastases
Previously, we introduced the mutant CYLDC/S complementary
DNA in the PDVC57 cell line. This mutant carries the 601C/S
point mutation in the cysteine box of the deubiquitinase
domain, resulting in a catalitically inactive protein that is able
to compete with the endogenous CYLD. We found that the
expression of the CYLDC/S mutant makes the squamous cancer
PDVC57 cells (SCC cells) very aggressive, conferring them
properties such as capacity of growing in suspension and
increased angiogenesis that finally leads to a rapid tumor
development in carcinogenesis assays (Alameda et al., 2010,
2011a). Now we have performed in vivo metastasis assays to
ascertain whether CYLD has a role in the metastatic behavior
of SCC epidermal cells. We injected the C57-Control cell
(expressing the empty vector) and C57-CYLDC/S cells
(expressing the CYLDC/S transgene) in the tail vein of immuno-
deficient mice. Soon after injection (18 days), 33% of the
C57-CYLDC/S -injected mice showed cachexia, being extre-
mely thin and displaying evident breathing difficulties. The
autopsy of the animals showed enlarged lungs of brownish-red
color, with a dried appearance and hard consistency
(Figure 1a); moreover, lungs injected with the C57-CYLDC/S
cells appeared full of metastases that covered almost all its
surface (Figure 1b). The appearance of these lungs was in sharp
contrast with the whitish, spongy, and moist appearance of the
lungs injected with the C57-Control cells (Figure 1a).
The histological analysis of the lungs of the injected mice
showed that the C57-Control cells also led to the development
of metastasis (C57-Control-metastases). However, the area
occupied by the C57-CYLDC/S-metastases (metastasis origi-
nated by the injection of the C57-CYLDC/S cells) was nearly
90% versus 10% of the area occupied by the C57-Control-
metastases (Supplementary Table S1 online). The C57-CYLDC/
S cells invading the lungs formed pleomorphic, poorly differ-
entiated SCCs (Figure 1e and f). In contrast, the C57-Control
cells formed moderate to well-differentiated SCCs (Figure 1c
and d). To further confirm that the metastatic masses observed
in the lungs were epidermal cells, we performed immuno-
staining with keratin K5, characteristic of basal keratinocytes
of stratified epithelia such as skin and also expressed in SCCs,
but not present in the lungs. C57-CYLDC/S-metastasis showed
extensive staining of K5 (Figure 2c), similar to that found in
C57-SCCs (Figure 2a), demonstrating a massive colonization
of the lung tissue by epidermal-origin C57-CYLDC/S cells. In
contrast, C57-Control-metastasis only showed small colonies
of epidermal cells positive for K5 (Figure 2e). K6, a keratin
expressed by epidermal cells subjected to stress or proliferative
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Figure 1. Histological characterization of lungs injected with C57-CYLDC/S
and C57-Control cells. (a) Representative image of the macroscopic
appearance of lungs injected with C57-CYLDC/S or C57-Control cells collected
18 days after injection of the corresponding C57 cells. Note that each lung
injected with the C57-CYLDC/S cells doubles the size of the lungs injected with
the C57-Control cells. (b) Detail of the abundant metastasis (white nodules)
present in the lungs injected with the C57-CYLDC/S cells. (c–f) Hematoxylin–
eosin staining of sections corresponding to (c, d) C57-Control metastasis and
(e, f) C57-CYLDC/S metastasis. (e) Note the C57-CYLDC/S tumor cells breaking
through a blood vessel wall. Observe the scarce normal lung tissue remaining
in the lungs injected with the C57-CYLDC/S cells. L, lung tissue; T, tumor mass.
Bars¼ 300mm.
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Figure 2. CYLD expression in normal lungs and lung metastasis; characterization of lung metastasis. (a, b) Keratin 5 and 6 (K5 and K6) staining of the squamous
cell carcinomas (SCCs) obtained by subcutaneous inoculation of C57 cells in nude mice. (c–f) K5 and K6 staining showing the epidermal nature of the metastasis.
(g, h) CYLD expression in normal lungs. It is detected in the apical epithelium of the bronchioles (B), pneumocytes type I of the alveoli (A, arrowheads), and in
macrophages (arrows). (i, j) CYLD expression in the (i) Control-metastasis and (j) CYLDC/S–metastasis. (k) Immunoblot comparing CYLD, Snail, and Maspin
expression in lungs containing both C57-Control and CYLDC/S-metastases (collected 26 days after injection). L, lung tissue; T, tumor mass. Bars: (a–f)¼ 350mm;
(g, h)¼ 200mm; (i, j)¼300mm.
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conditions and skin SCCs (Figure 2b), was also detected in the
metastases invading the lungs (Figures 2d and f), further
confirming the epidermal origin of the tumoral masses.
We next analyzed by immunohistochemistry the expression
of CYLD in normal lungs as well as in C57-Control-metastases
and C57-CYLDC/S-metastases. In the normal lungs, we found
that CYLD was expressed in the epithelium of the bronchioles
(in particular in the apical region; Figure 2g) as well as
in the type I pneumocytes of the alveoli and in macro-
phages (Figure 2h). This pattern of expression was also
detected in lungs carrying C57-Control-metastasis
(Supplementary Figure 1a online); however, endogenous CYLD
was weakly detected in lungs carrying C57-CYLDC/S-metastasis
(Supplementary Figure1b online). We found elevated expres-
sion of CYLD in the epidermal cancer cells forming the
C57-CYLDC/S-metastasis (Figure 2j), whereas in the C57-
Control-metastasis only small aggregates of tumor cells positive
for CYLD staining were found (Figure 2i) Figure 2k shows a
western blot also indicating the increased CYLD expression in
the C57-CYLDC/S-metastasis.
In addition to lung, other tissues were analyzed (kidney and
brain) and no metastases were found (data not shown).
C57-CYLDC/S-metastases show markers distinctive of highly
aggressive epidermal tumors such as increased angiogenesis,
induction of Snail and keratins K8/K13, and decreased
expression of Maspin
We analyzed the expression of markers of malignancy of SCCs
such as keratins K8 and K13 in the lung metastases. K8 is
characteristic of simple epithelia (Moll et al., 1982); although
it is not expressed in epidermis, it is frequently detected in skin
tumors, with this aberrant expression being considered a
marker of malignancy (Casanova et al., 2004). In lung tissue,
K8 was detected in the respiratory epithelium that lines the
bronchi, bronchioles, and alveoli, as expected (Casanova
et al., 1995). K8 was not detected in the C57-Control epider-
mal cells invading the lungs (Figure 3a); however, it was
strongly expressed in the tumor cells of the C57-CYLDC/S-
metastasis, indicating its high grade of malignancy (Figure 3b).
K13 are a keratin characteristic of internal stratified squamous
epithelia that is aberrantly expressed in skin tumors and are
also considered a marker of tumor progression (Winter et al.,
1990; Moreno-Maldonado et al., 2008). We found K13-
positive cells in the C57-CYLDC/S-tumoral masses invading
the lungs (Figure 3d), whereas it was not detected in the
C57-Control-metastasis (Figure 3c). We also found that
C57-CYLDC/S-metastasis were highly proliferative as indicated
by the elevated number of positive cells for Ki67 (Figure 3f)
compared with that detected in the C57-Control-metastasis
(Figure 3e).
Another factor that contributes to increase the aggressive-
ness of SCCs is the presence of a strong vascularization
(Bolontrade et al., 1998). We have analyzed by smooth
muscle actin immunostaining the pattern of blood vessels in
both C57-Control-metastasis and CYLDC/S-metastasis and
found that C57-CYLDC/S-metastases were highly vascularized
(Figure 3h), whereas we hardly detected smooth muscle actin–
positive staining in the C57-Control-metastasis (Figure 3g).
This result is in agreement with our previous finding showing
an enhanced angiogenesis in the skin tumors obtained by
subcutaneous inoculation of both the murine C57 and human
A431 SCC cells expressing the CYLDC/S mutant (Alameda
et al., 2010, 2011a).
As it has been described that Snail develops an important
role in mouse skin tumor progression and invasion (Peinado
et al., 2004; Roy et al., 2004; Barrallo-Gimeno and Nieto,
2005), we analyzed by both immunohistochemistry and
western blot whether Snail was expressed in the metastasis.
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Figure 3. Analysis of markers of malignancy in C57-Control and
C57-CYLDC/Smetastases. (a, b) Keratin 8 (K8) immunostaining. (c, d) Keratin 13
(K13) staining. (e, f) Ki67 staining showing the proliferation rate of the C57-
control and C57-CYLDC/S-metastasis. (g, h) Smooth muscle actin (SMA)
staining of the blood vessels of C57-Control-metastasis and CYLDC/S-metastasis
is used as indicative of the tumor angiogenesis. Note the strong vascularization
of the metastasis expressing the mutant CYLDC/S. Snail expression was detected
in the (j) C57-CYLDC/S-metastasis but not in the (i) C57-Control-metastasis.
(l) Observe the diminished expression of Maspin in the CYLDC/S squamous cell
carcinomas (SCCs). (m, n) K5 staining shows the extension of the
C57-Control-metastasis and CYLDC/S-metastasis. A, alveoli; L, lung tissue;
T, tumor mass. Bars: (a–d)¼ 350mm; (e, f)¼250mm; (g–j)¼200mm;
(k–n)¼ 300mm.
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We found elevated expression of Snail in the C57-CYLDC/S-
metastasis, whereas it was not detected in the C57-Control-
metastasis, therefore suggesting a more aggressive phenotype
of the C57-CYLDC/S-metastasis (Figures 2k and 3i and j).
We have recently found a correlation between decreased
levels of Maspin and increased malignancy of epidermal
tumors in mice (Alameda et al., 2011a). We then checked
the expression of Maspin in the metastasis and found that
it was strongly expressed in the C57-Control-metastasis
(Figure 3k), almost in the whole tumor mass (denoted by the
K5 expression area, Figure 3m); in contrast, it showed a weak
expression in the tumor cells of C57-CYLDC/S-metastasis
(Figure 3l), in spite of the large size of the SCCs (indicated
by K5 expression, Figure 3n). Western blot analysis also
showed decreased levels of Maspin in C57-CYLDC/S-metasta-
sis (Figure 2k).
CYLD lack of function directly correlates with Maspin decreased
expression in epidermal SCC cells
The above analysis shows striking differences between
C57-Control and C57-CYLDC/S metastasis for expression of
two important proteins for metastasis progression, i.e., Snail
and Maspin. We have then examined whether the changes in
the expression of both Snail and Maspin have previously taken
place in the C57-CYLDC/S cells growing in monolayer cul-
tures. qPCR analysis showed a 4-fold increase in the expres-
sion of Snail in the C57-CYLDC/S cells with respect to that in
the C57-Control cells (Figure 4a). However, we could not
detect Snail protein by western blot in C57-Control cells nor in
C57-CYLDC/S cells (Figure 4b) growing in monolayer cultures.
The analysis of Maspin expression by qPCR showed that levels
were not significantly different between C57-control or
C57-CYLDC/S cells (data not shown). However, the analysis
of Maspin protein showed that the C57-CYLDC/S cells express
lower levels of Maspin than the C57-Control cells (Figure 4c).
To discard a cell type–specific effect, we studied whether the
mutant CYLD isoform affected the expression of Maspin in
two other cell lines: the A431 SCC cells and the murine PB
cells (these cell lines were transfected with the CYLDC/S
construct and A431-CYLDC/S and PB-CYLDC/S clones iso-
lated). We found that effectively, both A431-CYLDC/S and
PB-CYLDC/S cells exhibited lower levels of Maspin expression
than their respective controls (A431-Control and PB-Control
cells; Figures 4d and e). These results indicate a correlation
between the loss of the catalytic function of CYLD and the
diminished expression of Maspin in tumor SCC cells. We then
analyzed whether the overexpression of exogenous wild-type
CYLD in SCC cells has the opposite effect. For this purpose,
we studied the expression of Maspin in A431-CYLDWT cells
(A431 cells overexpressing the CYLD wild-type complemen-
tary DNA) (described in Alameda et al., 2011a) and observed
higher levels of Maspin expression in these cells as compared
with A431-Control cells (Figure 4d). Therefore, our results
show that the impairment of the deubiquitination function of
CYLD in SCC cells as a result of CYLDC/S expression is
accompanied by a decrease in the expression of Maspin
protein in these tumor cells and, conversely, the exogenously
increased CYLD wild-type expression correlates with an
increased expression of Maspin. According to these results,
we have performed immunoprecipitation experiments that
suggest a possible physical interaction between CYLD and
Maspin (Supplementary Figure S2 online).
In order to analyze whether the reduction in the expression
of Maspin in the C57-CYLDC/S cells could be a reason for their
highly malignancy, we have transfected them with a com-
plementary DNA of Maspin. Double transfectans, C57-
CYLDC/S-Maspin cells, were selected (Figure 4g). A reduction
in the proliferation rate of the double transfectans was
observed in monolayer cultures of C57-CYLDC/S–Maspin cells
compared with both C57-Control and C57-CYLDC/S cells
(Figure 4h). The metastasis assays in nude mice showed that
whereas the C57-CYLDC/S cells developed abundant foci of
metastasis by day 5 after injection (Figure 4j and
Supplementary Table S2 online), the C57-CYLDC/S–Maspin
cells only originate few small metastases per lung (Figure 4k,
Supplementary Table S2 online). At this time, C57-Control
cells also develop metastases, although less numerous and
smaller in size than the C57-CYLDC/S cells (Figure 4i,
Supplementary Table S2 online). K5 staining confirmed the
epidermal nature of the metastases (Figure 4i–k). We have also
detected a diminished vascularization of the C57-CYLDC/S–
Maspin metastasis with respect to that of the C57-CYLDC/S
metastasis (Supplementary Figure S3 online).
An inverse relationship between levels of Maspin expression and
the grade of malignancy of epidermal cells is detected in
different cell lines
As the expression of Maspin in epidermal cells has not been
explored yet, we studied whether a relationship exists
between Maspin expression and the grade of malignancy of
epidermal tumor cells. We found that both murine (MCA3D)
and human (HaCaT) nontumoral cells expressed higher levels
of Maspin than the tumoral cells. The tumor SCC13 human
cells, which are less aggressive than the A431 cells, express
higher levels of Maspin (Figure 4f). We also found that C57
murine tumor cells expressed lower levels of Maspin than
normal mouse skin and MCA3D cells; and the very aggressive
HaCa4 SCC cells express low levels of Maspin (Figure 4f).
Overall, our results establish a decreased expression of Maspin
with increasing tumor epidermal cell malignancy, suggesting
that the low levels of Maspin expression results in a more
invasive phenotype.
Maspin expression is decreased in human cylindromas,
trichoepitheliomas, and spiradenomas defective in CYLD
function
In order to analyze whether there is a correlation in vivo
between CYLD lack of function and a decrease in Maspin
expression, we studied the expression of Maspin in cylindro-
mas, spiradenomas, and trichoepitheliomas (lacking CYLD
deubiquitinase function). Skin from healthy donors showed
that Maspin was mainly expressed in the suprabasal, differ-
entiated layers of the epidermis, and in the inner root sheath of
hair follicles (Figure 5a; compare with the K14 basal staining
and the suprabasal K10 expression, Figure 5b and c). Staining
of the cylindromatosis tumors showed that Maspin was
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strongly expressed in the adjacent healthy epidermis, whereas
it was weakly expressed in the tumoral cells of the three types
of neoplasias (Figure 5g–l). In cylindromas and trichoepithe-
liomas, Maspin was only located in the inner parts of the
tumor islands that are the more differentiated regions
(Figure 5g, j, h, and k). In spiradenomas, scarce Maspin
expression was detected in sporadic cells of the tumor
compared with the high and continuous expression seen in
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the epidermis and the eccrine glands (Figure 5i and l). We
observed that keratin K5 and K10 expression was also down-
regulated in most of the tumor islets of the three types of
familial cylindromatosis tumors (Figure 5m–r). These results
show that, as occurs in CYLDC/S tumor cells, where the lack of
the deubiquitination function of CYLD was accompanied by
diminished expression of Maspin, in tumor cells of cylindro-
matosis patients carrying a functionally similar inactivating
mutation in the CYLD gene (Rajan et al., 2009), a decreased
expression of Maspin was also observed.
DISCUSSION
Here we describe that in in vivo metastasis experiments in
nude mice, the epidermal C57-CYLDC/S cells lacking the
deubiquitinase function of CYLD leads to very aggressive
metastasis in lung. Previously, we had found that lack of CYLD
function in epidermal cells leads to an increase in several
angiogenic factors such as vascular endothelial growth factor;
it also makes the cells resistant to apoptosis, increases their
proliferation, and induces the delocalization of adhesion
proteins (E-cadherin and b-catenin) (Alameda et al., 2010,
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2011a). Altogether, the combination of all these alterations
could be responsible for the great increase
in the metastatic potential of the C57-CYLDC/S cells. In
addition, we have now found decreased expression of
Maspin in the C57-CYLDC/S cells, which appears as an
important factor for the increased malignancy of the
C57-CYLDC/S cells, as restoration of Maspin expression in
C57-CYLDC/S cells results in reduction in the number and
extension of metastases in the lung.
We have found evidences indicating a direct correlation
between the lack of CYLD function as a consequence of the
expression of the mutant CYLDC/S in SCC cells and the
diminished expression of Maspin (Figure 4c–e). Moreover,
our results also show that the exogenous overexpression
of CYLDWT in SCC cells correlates with increased levels
of Maspin (Figure 4d). Remarkably, we have found loss of
Maspin expression in the CYLD-deficient tumors (cylindromas,
trichoepitheliomas, and spiradenomas) compared with the
expression in normal human skin, indicating a correlation
in vivo between the deficient CYLD function and the decrease
in Maspin expression as well. The fact that most of the
hereditary cylindromatosis patients do not develop metastasis
may be likely because of the lack of additional mutations
(besides CYLD mutation) in this kind of tumors.
It had been reported that Maspin is an important inhibitor
of human tumor progression and metastasis in different
types of cancers such as breast, liver, and prostate carcinomas
(Luo et al., 2007; Stark et al., 2010). However, until
now, there is little information about the relation of Maspin
and skin cancer. Recently, we have reported a possible
relationship between Maspin downregulation and NMSC
progression in vivo in mouse skin carcinogenesis assays
(Alameda et al., 2011b). Here we have found a correlation
between decreased expression of Maspin and increased
malignancy of mouse and human tumor epidermal cells.
These results suggest that the levels of Maspin expression
could be an important predictive tool in the course of the
NMSC progression and metastasis.
We have found that a relationship exists between lack of
CYLD function in epidermal SCCs and increased lung meta-
static capacity of the tumor cells. Our results contribute to the
understanding of the molecular biology of SCC epidermal
metastasis, assigning a role for CYLD as suppressor of lung
metastasis in addition to its implication in the familial
cylindromatosis disease. Our data suggest that the reduction
in the levels of Maspin expression in the C57-CYLDC/S
cells—along with the other changes previously described to
occur in the C57 cells as a consequence of CYLDC/S
expression—plays an important role in the acquisition of high
metastatic potential of these cells.
MATERIALS AND METHODS
Cell lines and culture conditions
C57, A431, and PB cells were cultured in DMEM supplemented with
10% fetal calf serum. Transfected cells were grown in the presence of
0.4 mg of G418 per ml for single transfection or 0.4 mg of G418 per
ml plus 0.1 mg of Hygromciyn B per ml for double transfection (C57-
CYLDC/S–Maspin cells). C57-Control, C57-CYLDC/S, A431-Control,
A431-CYLDC/S, and A431-CYLDWT cells have been already described
(Alameda et al., 2010, 2011a).
DNA constructs
Constructs employed have been previously described (Alameda et al.,
2010, 2011a). Maspin complementary DNA of rat origin (Tokuyama
et al., 2007) was subcloned into the pcDNA3-hygromycin (Invitrogen,
Carlsbad, CA).
Metastasis assays
First time, 5 105 C57-Control and C57-CYLDC/S cells were resus-
pended in 100ml of phosphate-buffered saline and injected intrave-
nously into the tail vein. A total of 10 nude mice (Hsd-Athymic Nude,
Harlan Europe, Barcelona, Spain) were injected with cells of each
phenotype. For metastasis experiments with C57-Control, C57-
CYLDC/S, and C57-CYLDC/S–Maspin cells (Figure 4i–k), 5 105 cells
of each genotype were resuspended in 100ml of phosphate-buffered
saline and injected intravenously into the eye vein. Then, 7 nude
mice were injected with cells of each phenotype and samples were
recovered 5 and 10 days after injection. All experimental procedures
were performed according to European and Spanish laws.
Histology and immunohistochemistry
Formalin-fixed lungs were stained with hematoxylin and eosin for
histopathological evaluation and immunohistochemistry was per-
formed with the following antibodies: K5, K6, K10 (Covance, San
Diego, CA); CYLD (Sigma-Aldrich, St Louis, MO); K8, smooth muscle
actin (Sigma-Aldrich); K13, Snail (Abcam, Cambridge, UK); Ki67, K14
(NeoMarkers, Fremont, CA); and Maspin (Santa Cruz Biotechnology,
Heidelberg, Germany). Stainings with CYLD and Snail antibodies
were performed in cryosections fixed in methanol/acetone.
Western blot analysis
Antibodies used were: Actin, Maspin, Snail, rabbit IgG (Santa Cruz
Biotechnology, Europe); CYLD (SAB4200060, SAB4200061); and
tubulin (Sigma-Aldrich). A total of 40–50mg of total lysate was used.
Total protein extracts (300mg) were immunoprecipitated with an
antibody specific for CYLD (SAB4200060 or SAB4200061) or Maspin.
These three antibodies were produced in rabbit. Proteins were
resolved on an SDS gel; probed with anti-Maspin and CYLD
SAB4200060 or CYLD (sc-25779, Santa Cruz Biotechnology) anti-
bodies. As control of specificity, samples (300mg) were immunopre-
cipitated with rabbit IgG.
Quantitative PCR
RNA was extracted from cells using trizol followed by purification by
RNeasy columns. RNA was reverse transcribed using the ABI High-
Capacity Kit (ABI, Foster City, CA). Real-Time PCR was performed
using predesigned Taqman assays in an ABI 7500Fast instrument,
using the conditions indicated by ABI.
Human tissue samples
For formalin-fixed, paraffin-embedded skin and tumor samples,
archival paraffin blocks were obtained from the biobank of the
Fundacio´n Jime´nez Dı´az (Madrid, Spain). All experimentation was
approved by the Research Committee of the Hospital Fundacio´n
Jime´nez Dı´az, and this study has been designed and performed
following Declaration of Helsinki Principles for human research in
their revised form.
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